Literature DB >> 18520805

RETRACTED: Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.

Tianhong Li1, Yi-He Ling, Roman Perez-Soler.   

Abstract

The Journal of Thoracic Oncology was alerted on August 16, 2021 that Figures 1 and 3 in this article are suspected of image manipulation. The editorial team promptly consulted with the authors and publisher. The authors stand by the validity of the conclusions and the scientific merit of the manuscript but acknowledge that some Figures might not have been properly prepared. Therefore, the editorial team asserts that the conclusions could be unreliable.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520805     DOI: 10.1097/JTO.0b013e3181753b24

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  12 in total

1.  Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer.

Authors:  Alexandre F Aissa; Abul B M M K Islam; Majd M Ariss; Cammille C Go; Alexandra E Rader; Ryan D Conrardy; Alexa M Gajda; Carlota Rubio-Perez; Klara Valyi-Nagy; Mary Pasquinelli; Lawrence E Feldman; Stefan J Green; Nuria Lopez-Bigas; Maxim V Frolov; Elizaveta V Benevolenskaya
Journal:  Nat Commun       Date:  2021-03-12       Impact factor: 14.919

2.  pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations.

Authors:  Gabriella Aquino; Giuseppe Pannone; Angela Santoro; Giuseppina Liguori; Renato Franco; Rosario Serpico; Gianluca Florio; Alfredo De Rosa; Marilena Mattoni; Valentina Cozza; Gerardo Botti; Simona Losito; Francesco Longo; Stefania Staibano; Giovanni Cuda; Lorenzo Lo Muzio; Carolina Sbordone; Pantaleo Bufo; Anna Grimaldi; Michele Caraglia; Marina Di Domenico
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

3.  Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response.

Authors:  Xu Zhang; Tapan Maity; Manoj K Kashyap; Mukesh Bansal; Abhilash Venugopalan; Sahib Singh; Shivangi Awasthi; Arivusudar Marimuthu; Harrys Kishore Charles Jacob; Natalya Belkina; Stephanie Pitts; Constance M Cultraro; Shaojian Gao; Guldal Kirkali; Romi Biswas; Raghothama Chaerkady; Andrea Califano; Akhilesh Pandey; Udayan Guha
Journal:  Mol Cell Proteomics       Date:  2017-03-22       Impact factor: 5.911

4.  Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy.

Authors:  Lea Olive Tchouate Gainkam; Marleen Keyaerts; Vicky Caveliers; Nick Devoogdt; Christian Vanhove; Leo Van Grunsven; Serge Muyldermans; Tony Lahoutte
Journal:  Mol Imaging Biol       Date:  2011-10       Impact factor: 3.488

5.  Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.

Authors:  Guolin Zhang; Bin Fang; Richard Z Liu; Huiyi Lin; Fumi Kinose; Yun Bai; Umut Oguz; Elizabeth R Remily-Wood; Jiannong Li; Soner Altiok; Steven Eschrich; John Koomen; Eric B Haura
Journal:  J Proteome Res       Date:  2010-12-03       Impact factor: 4.466

6.  Genomic-wide analysis of lymphatic metastasis-associated genes in human hepatocellular carcinoma.

Authors:  Chun Feng Lee; Zhi Qiang Ling; Ting Zhao; Shih Hua Fang; Weng Cheng Chang; San Chih Lee; Kuan Rong Lee
Journal:  World J Gastroenterol       Date:  2009-01-21       Impact factor: 5.742

7.  The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.

Authors:  Yiyu Zou; Yi-He Ling; Juan Sironi; Edward L Schwartz; Roman Perez-Soler; Bilal Piperdi
Journal:  J Thorac Oncol       Date:  2013-06       Impact factor: 15.609

8.  Retracted Article: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells.

Authors:  Guimin Chen; Lei Ye; Yufei Han; Ping Han
Journal:  RSC Adv       Date:  2019-07-05       Impact factor: 4.036

9.  LncRNA SOX2-OT regulates AKT/ERK and SOX2/GLI-1 expression, hinders therapy, and worsens clinical prognosis in malignant lung diseases.

Authors:  Abril Marcela Herrera-Solorio; Irlanda Peralta-Arrieta; Leonel Armas López; Nallely Hernández-Cigala; Criselda Mendoza Milla; Blanca Ortiz Quintero; Rodrigo Catalán Cárdenas; Priscila Pineda Villegas; Evelyn Rodríguez Villanueva; Cynthia G Trejo Iriarte; Joaquín Zúñiga; Oscar Arrieta; Federico Ávila-Moreno
Journal:  Mol Oncol       Date:  2020-12-25       Impact factor: 6.603

10.  Mutation and drug-specific intracellular accumulation of EGFR predict clinical responses to tyrosine kinase inhibitors.

Authors:  Maurice de Wit; Ya Gao; Darlene Mercieca; Iris de Heer; Bart Valkenburg; Martin E van Royen; Joachim Aerts; Peter Sillevis Smitt; Pim French
Journal:  EBioMedicine       Date:  2020-06-05       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.